SCHEMBL29411469

SCHEMBL29411469

Cc1ccc(C(=O)NCCCc2cccc(-c3ccc4c(cnn4C)c3)c2)cn1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PTAFR P25105 6/20 0.48
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.45
CYP19A1 P11511 1/20 0.45
KDM4B O94953 1/20 0.44
AR P10275 2/20 0.43
F10 P00742 1/20 0.43
LMNA P02545 1/20 0.42
NAMPT P43490 2/20 0.42
WNT1 P04628 1/20 0.41
CLK2 P49760 1/20 0.41
CLK3 P49761 1/20 0.41
GSK3B P49841 1/20 0.41
DYRK1A Q13627 1/20 0.41
EPHX2 P34913 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21045576 1.00 PTAFR (0.48) PTAFRKDM4EALDH1A1CYP19A1KDM4B
SCHEMBL21045501 0.92 KDM4E (0.50) PTAFRKDM4EALDH1A1CYP19A1AR
SCHEMBL21045187 0.84 PTAFR (0.40) PTAFRARF10LMNAWNT1
SCHEMBL29411479 0.84 PTAFR (0.40) PTAFRARF10LMNAWNT1
SCHEMBL21045250 0.82 PTAFR (0.52) PTAFRKDM4EALDH1A1CYP19A1KDM4B
SCHEMBL29411440 0.82 PTAFR (0.52) PTAFRKDM4EALDH1A1CYP19A1KDM4B
SCHEMBL29411591 0.81 PTAFR (0.62) PTAFRKDM4EALDH1A1CYP19A1F10
SCHEMBL21045299 0.81 PTAFR (0.62) PTAFRKDM4EALDH1A1CYP19A1F10
SCHEMBL21045340 0.81 PTAFR (0.59) PTAFRKDM4EALDH1A1CYP19A1KDM4B
SCHEMBL29411467 0.81 PTAFR (0.59) PTAFRKDM4EALDH1A1CYP19A1KDM4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188035-A1 TUBULIN INHIBITORS LIN BIOSCIENCE LLC (US) 2025-06-12 US disclosed
US-12247010-B2 Tubulin inhibitors LIN BIOSCIENCE INC. (TW) 2025-03-11 US disclosed
US-20220089539-A1 TUBULIN INHIBITORS LIN BIOSCIENCE INC. (TW) 2022-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089539-A1 TUBULIN INHIBITORS TUBB3, TUBB1, TUBB PTAFR 2124/4885KDM4E 4032/4885ALDH1A1 3048/4885
US-12247010-B2 Tubulin inhibitors TUBB3, TUBB1, TUBB PTAFR 2124/4885KDM4E 4032/4885ALDH1A1 3048/4885
US-20250188035-A1 TUBULIN INHIBITORS TUBB3, TUBB1, TUBB PTAFR 2124/4885KDM4E 4032/4885ALDH1A1 3048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.